Monitor the pace of ATM sales via quarterly filings to gauge dilution pressure. The BLA submission for Zenkuda in Q4 2026 and KSI-101 Phase 3 data in December 2026 are the key catalysts that could offset dilution concerns.
Price Chart
Executive Summary
Kodiak Sciences filed an automatic shelf registration (S-3ASR) on October 20, 2026, registering an unlimited amount of securities, and concurrently entered into an at-the-market (ATM) distribution agreement with J.P. Morgan to sell up to $350 million of common stock. The company is a pre-commercial biotech with three late-stage retinal programs and plans to submit a BLA for Zenkuda in Q4 2026. The ATM provides capital flexibility ahead of potential commercialization, but introduces dilution risk.
Key Facts
- Filed S-3ASR shelf registration for unlimited securities on October 20, 2026.
- Entered into an ATM distribution agreement with J.P. Morgan to sell up to $350,000,000 of common stock.
- J.P. Morgan will receive up to 3% of gross proceeds as compensation.
- Stock price on October 19, 2026 was $91.35 per share.
- Company is pre-commercial with no revenue, planning BLA submission for Zenkuda in Q4 2026.
- Net tangible book value as of June 30, 2026 was $61.1 million ($0.97 per share).
- Pro forma net tangible book value after full ATM issuance would be $400.2 million ($6.00 per share).
- Dilution to new investors at assumed $91.35 price would be $85.35 per share.
- Prior 10-K (Dec 31, 2025) included a going concern explanatory paragraph from auditors.
Financial Impact
Up to $350 million in potential common stock sales; full issuance would increase shares outstanding by ~6.1% from 62.8M to ~66.7M shares.
Risk Factors
- Dilution from potential ATM sales could pressure stock price.
- Pre-commercial stage with no revenue; going concern risk noted in prior audit.
- BLA submission and regulatory approval for Zenkuda are uncertain.
- Competition from existing anti-VEGF therapies (Eylea, Vabysmo) and other pipeline candidates.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-426854 |
| Document: d143488dex43.htm | 0001193125-26-426854 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | S-3ASR | $87.72 $85.78 | ▲ +2.21% | ▲ +1.03% | $90.68 (−3.37%) |
Sep 30, 2026 25d ago | SC 13D/A | $98.46 $94.45 | ▼ −4.07% | ▼ −4.81% | $90.68 (−7.91%) |
Sep 30, 2026 26d ago | Insider Buy | $98.46 $94.45 | ▼ −4.07% | ▼ −4.81% | $90.68 (−7.91%) |
Sep 28, 2026 28d ago | 8-K | $89.92 $91.12 | ▲ +1.33% | ▲ +1.52% | $90.68 (+0.84%) |
Aug 13, 2026 10w ago | 8-K | $41.35 $40.98 | ▼ −0.89% | ▼ −0.42% | $90.68 (+119.29%) |
Aug 13, 2026 10w ago | Press Release | $41.35 $40.98 | ▼ −0.89% | ▼ −0.42% | $90.68 (+119.29%) |
Jun 11, 2026 19w ago | Institutional Cluster | $33.97 $34.06 | ▲ +0.26% | ▼ −0.28% | $90.68 (+166.93%) |
May 7, 2026 24w ago | 8-K | $41.01 $39.85 | ▼ −2.83% | ▼ −3.06% | $90.68 (+121.10%) |
Mar 31, 2026 29w ago | 8-K | $42.81 $40.63 | ▼ −5.09% | ▼ −5.17% | $90.68 (+111.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers